Peptide News Digest

#Nad

2 stories

Regulatory · View digest

FOX Carolina: Greenville Woman Reports Dark Skin Spots After Ordering Melanotan, Retatrutide, and NAD+ Online

Ashley Sams told FOX Carolina she noticed dark spots on her neck, back, stomach, and legs after buying melanotan, the investigational weight-loss drug retatrutide, and NAD+ online, and that one product left her short of breath. Her doctor, Nita Bijoor, told her to stop all of them and see a dermatologist, noting that many such products are labeled for research use only. None of the products is FDA-approved, and none is among the six peptides covered by HHS's new compounding policy.

Industry · View digest

Sacred Eye Beauty 30-Day Ritual Launches Sunday June 28 with Inside-Out Activator (NAD+, Spermidine, Vitamin C, MODS Max Sublingual Delivery) Paired with Skin Magic Tablets Containing GHK-Cu Copper Peptide, PQQ, and Methylene Blue; Mainstream Consumer Cosmetic Peptide Wave Extends to Inside-Out Longevity Claims

Fast Millennial Mode LLC, founded by entrepreneur Elena Catalina Radu, announced the official launch of Sacred Eye Beauty's flagship 30-Day Ritual on Sunday June 28, 2026. The system has two components. The Inside-Out Activator combines NAD+, spermidine, vitamin C, and MODS Max sublingual-delivery technology in a single daily dose targeting cellular-wellness and healthy-aging markers. The Skin Magic Tablets combine GHK-Cu (copper tripeptide-1), PQQ (pyrroloquinoline quinone), and methylene blue for skin and broader cellular support. The launch fits squarely inside the 2026 mainstream-consumer cosmetic peptide wave that this site has tracked across June: Moes Group's June 6 GHK-Cu private-label manufacturing rollout, CKYN's June 20 GHK-Cu launch, Cosmetics Business's June 2026 feature on eight peptide-anchored beauty launches (Shiseido Ultimune, YSE Beauty Xtreme Glow), and the K-beauty PDRN-peptide-exosome stack. Sacred Eye's differentiator is the inside-out positioning, pairing oral supplementation with topical-equivalent claims. The consumer-channel growth runs in parallel to the regulatory thread: GHK-Cu is one of the seven peptides on the FDA Pharmacy Compounding Advisory Committee's July 23-24 agenda for 503A bulks list eligibility.